{"id":4400,"date":"2018-06-15T10:05:48","date_gmt":"2018-06-15T14:05:48","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4400"},"modified":"2018-06-15T10:05:48","modified_gmt":"2018-06-15T14:05:48","slug":"autolus-therapeutics-ipo-preview-autl","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/autolus-therapeutics-ipo-preview-autl\/","title":{"rendered":"Autolus Therapeutics #IPO Preview ($AUTL)"},"content":{"rendered":"<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.jpg\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-4401\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.jpg\" alt=\"AUTL\" width=\"219\" height=\"51\" \/><\/a><\/p>\n<p>Company: <strong>Autolus Therapeutics Limited<\/strong><br \/>\nSymbol: AUTL<br \/>\nDescription: They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.<br \/>\nTrade Date: 6\/22<br \/>\nShares: 7.81 million<br \/>\nPrice Range: $15.00-$17.00<br \/>\nUnderwriter(s): Goldman Sachs &amp; Co., Jefferies<br \/>\nCo-Manager(s): Wells Fargo Securities, William Blair<br \/>\nTerms Added: 6-8-18<\/p>\n<p><strong><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1560258\/000119312518184430\/d472601ds1a.htm\" target=\"_blank\">Link to Prospectus<\/a><\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.retailroadshow.com\/wp\/roadshows.asp\" target=\"_blank\">Link to Retail Roadshow<\/a><\/strong><\/p>\n<p><strong>Business<\/strong>:\u00a0They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using their broad suite of proprietary and modular T cell programming technologies, they are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. They believe their programmed T cell therapies have the potential to be\u00a0best-in-class\u00a0and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.<\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.Pipeline.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter size-full wp-image-4402\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.Pipeline.jpg\" alt=\"AUTL.Pipeline\" width=\"559\" height=\"469\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.Pipeline.jpg 559w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/06\/AUTL.Pipeline-300x252.jpg 300w\" sizes=\"(max-width: 559px) 100vw, 559px\" \/><\/a><\/p>\n<p><strong>Insider Buying:<\/strong>\u00a0Certain of their\u00a0existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $60\u00a0million in shares of their\u00a0common stock in this offering at the initial public offering price per share.<\/p>\n<p><strong>Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><span style=\"font-weight: 400;\">IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n<p><strong>Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0<a href=\"https:\/\/www.ipoboutique.com\/cgi\/ipo-track-record-summary-report.php\"><span style=\"font-weight: 400;\">track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here&#8217;s a<a href=\"http:\/\/www.ipoboutique.com\/blog\/?p=3655\"> 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique&#8217;s service.<\/p>\n<p><b>Indicate with confidence,\u00a0<\/b><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><b>SUBSCRIBE<\/b><\/a><b>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company: Autolus Therapeutics Limited Symbol: AUTL Description: They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Trade Date: 6\/22 Shares: 7.81 million Price Range: $15.00-$17.00 Underwriter(s): Goldman Sachs &amp; Co., Jefferies Co-Manager(s): Wells Fargo Securities, William Blair Terms Added: 6-8-18 Link to Prospectus Link to Retail Roadshow Business:\u00a0They[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4400","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4400"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4400\/revisions"}],"predecessor-version":[{"id":4403,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4400\/revisions\/4403"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}